https://www.shionogimedical.com/ 2026-10-14 https://www.shionogimedical.com/disease-state 2026-10-14 https://www.shionogimedical.com/disease-state/gram-negative-infection 2026-10-14 https://www.shionogimedical.com/disease-state/covid-19 2026-10-14 https://www.shionogimedical.com/navigating-a-path-for-covid-19-background-management-and-prevention 2026-10-14 https://www.shionogimedical.com/resources/disease-state/covid-19/Early-Interventionin-COVID-19-may-reduce-clinical-complications-and-further-community-transmission 2026-10-14 https://www.shionogimedical.com/early-intervention-after-exposure-to-sars-cov-2-may-reduce-the-likelihood-of-developing-covid-19 2026-10-14 https://www.shionogimedical.com/disease-state/fragile-x-syndrome 2026-10-14 https://www.shionogimedical.com/product 2026-10-14 https://www.shionogimedical.com/product/fetroja-cefiderocol 2026-10-14 https://www.shionogimedical.com/product/xocova-ensitrelvir 2026-10-14 https://www.shionogimedical.com/overview-of-ensitrelvir 2026-10-14 https://www.shionogimedical.com/medical-information 2026-10-14 https://www.shionogimedical.com/congresses 2026-10-14 https://www.shionogimedical.com/publications 2026-10-14 https://www.shionogimedical.com/resources 2026-10-14 https://www.shionogimedical.com/resources/medical-writing-grants 2026-10-14 https://www.shionogimedical.com/resources/educational-grants 2026-10-14 https://www.shionogimedical.com/search 2026-10-14 https://www.shionogimedical.com/prescribing-information 2026-10-14 https://www.shionogimedical.com/medical-inquiry-form 2026-10-14 https://www.shionogimedical.com/request-msl 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-02/Disk_reading_guide_for_cefiderocol_verification_using_LSI_isolates_2.pdf?VersionId=4yk2FV6e707xBnRGBZw6WNTe.QyerSNb 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Oral%20Presentation%20-%20Nguyen%20ST%20et%20al.%20Society%20of%20Critical%20Care%20Medicine%202025.pdf?VersionId=4ajgmIVRyrG8LzBUIf7CdKhKvjpOeH2Z 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Oral%20Presentation%20-%20SCORPIO-PEP%20CROI%202025.pdf?VersionId=KbQ4yJis8foCkR0Kgn89tPOld6dYIu54 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Poster%20-%20Mendes%20RE%20et%20al.%20IDWeek%202024%20Sentry%20MBL%20CRE%20P1363.pdf?VersionId=OkBwV34pXCRhJViguJh6KxfOt_H_pw8W 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Poster%20-%20Mendes%20RE%20et%20al.%20IDWeek%202024%20Sentry%20US%20CRAB%20P1362.pdf?VersionId=pXP2v6BJP.sIltVqEB03nnoFjzBDkF8z 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Poster%20-%20Mendes%20RE%20et%20al.%20IDWeek%202024%20Sentry%20US%20PSA%20P1361%20(003).pdf?VersionId=u4teUktGU5BQWjRqLaxfjvWTAqPHqY05 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20carbapenem-resistant%20and%20molecularly%20characterized%20Enterobacterales%20isolates%20causing%20infections%20in%20hospitals%20in%20Europe%20and%20adjacent%20regions%202020to2023.pdf?VersionId=1hG7k4nceMpX.tFOpLF9D8BmSh82e22Y 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20clinical%20isolates%20of%20Acinetobacter%20baumannii%20complex%20collected%20from%20five%20European%20countries%20as%20part%20of%20the%20SENTRY%20antimicrobial%20surveillance%20programme%202020to2023.pdf?VersionId=Xp4JQaN6AWx20MLPjqWiuVkiC4ZL7WYD 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20clinical%20isolates%20of%20Pseudomonas%20aeruginosa%20collected%20from%20five%20European%20countries%20ENTRY%20antimicrobial%20surveillance%20programme%202020%20to%202023.pdf?VersionId=52P9fSM6xs0vtpBpx.fiHGIdLLR4bfHs 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20clinical%20isolates%20of%20Stenotrophomonas%20maltophilia%20collected%20from%20five%20European%20countries%20as%20part%20of%20the%20SENTRY%20antimicrobial%20surveillance%20programme%202020to2023.pdf?VersionId=ruOzvgwyPO_8mN568w.LmnCx9FaJzrBV 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20Enterobacterales%20carrying%20Multiple%20carbapenemases%20collected%20as%20part%20of%20the%20SENTRY%20antimicrobial%20surveillance%20program_0.pdf?VersionId=0kBmhkxizCitUM1_KrN6cLPUjulnH7c 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20metallo%20beta%20lactamase%20carrying%20nterobacterales%20stratified%20by%20allele%20collected%20as%20part%20of%20the%20SENTRY%20antimicrobial%20surveillance%20program.pdf?VersionId=utfsjzReiqPYkW1m3LQdVFm5WbkDwNaI 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Cefiderocol%20activity%20against%20resistant%20bacteria%20from%20patients%20with%20ventilator%20associated%20pneumonia%20from%20European%20and%20US%20hospitals.pdf?VersionId=3bKPnW1GjGdBadpWnWbXGqJzalz4VQD. 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Cefiderocol%20Breakpoints%20Slide.pdf?VersionId=V5A_RQfaTpDPezeAmfwkK7.Y_kn11w.V 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Cefiderocol%20treatment%20in%20patients%20with%20Gram_negative%20bacterial%20infections%20European%20results%20of%20the%20global%20retrospective%20observational%20PROVE%20study.pdf?VersionId=4tf1IaLy3PI_wyK4nrk3fjIV1VXQWSwH 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/CFDC%20QC%20Ranges%20Slide_FY2024.pdf?VersionId=O5V1t6CUXh0dkcrpu8G.WbwXzHnXYUf_ 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/ESCMID2025%20ensitrelvir%20Yamato.pdf?VersionId=yRMaPl0DfDd2aUYrt_NTZBKYUVF8RU.P 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/In%20vitro%20potency%20of%20ceftibuten%20with%20xeruborbactam%20against%20beta%20lactamase%20producing%20isolates%20of%20Enterobacterales%20%5BENT%5D%20from%20the%20SENTRY%20global%20surveillance%20programme.pdf?VersionId=tn6s537g2LPTR1ElXjfOZVLd5fxa2_Dn 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Phenotyping%20and%20genotyping%20analysis%20using%20baseline%20swab%20samples.pdf?VersionId=GGRz_GvH07Ek8nT5CUND_x.rcLjh72oB 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-06/Comparison%20of%20conventional%20and%20iron-%20depleted%20agar%20plates%20for%20susceptibility%20testing%20%20of%20cefiderocol%20by%20disk%20diffusion.pdf?VersionId=oHPjyRvmFDYL3XjiFR_nsI.Fre8X9uGy 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-07/COVID-19%20Infographic%20%231%20-%20Omicron%20Transmission-SAR.%20The%20Burden%20of%20COVID-19.pdf?VersionId=VatL6ImnPJuW26CkN8rN8aPib1XJkijs 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-08/COVID-19%20Infographic%20%232%20-%20COVID-19%20Worsens%20Underlying%20Conditions_0.pdf?VersionId=iu9Bp7J8JaJnFHCzELUdbpJ0qan7vwo. 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-09/Ensitrelvir%20for%20the%20Prevention%20of%20COVID-19%20Among%20Household%20-%201.pdf?VersionId=XDfVKYuA1ZncrODAs6RrR.DgY_cKFQhj 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/ASCP%202025_P14_Current%20Impact%20of%20COVID-19%20in%20Long-Term%20Care%20Facilities.pdf?VersionId=C716CnSNCEx9RDJtw8Iddhj_Unf7FQ86 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/AVG%20and%20IMRP%202025_P12_Real-world%20Impact%20of%20Early%20Outpatient%20COVID-19%20Antiviral%20Treatment.pdf?VersionId=LneA._fqF1UXaNVtt_TQFgKUex0h2Tgm 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1186_Pharmacodynamic%20Assessment%20of%20Combination%20of%20Cefiderocol%20.pdf?VersionId=UfC9xE12Bmv5.PFmIqNfelZDNp737H_E 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1198_Inner%20Zones%20of%20Inhibition%20in%20Disk%20Diffusion%20Testing%20of%20Cefiderocol.pdf?VersionId=DlPbbqQLkHRr.IFbMI9iAJCm4iiBoSda 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1220_Analyzing%20Trends%20of%20Cefiderocol%20Susceptibility%20.pdf?VersionId=ZpwX7z66h.6Jw18N5rKs9utCij3MrM_B 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1221_In%20Vitro%20Activity%20of%20Cefiderocol%20Against%20Clinical%20Strains.pdf?VersionId=0EJYK0aHG5iT0PxhcXB0_f8YY7Lb7DqA 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1222_Population%20Pharmacokinetic_Pharmacodynamic%20Analysis%20of%20Cefiderocol.pdf?VersionId=vMn.Gtu8ExBz.ixrgzicAmNIrN1uvnxO 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1278_Activity%20of%20cefiderocol%20and%20comparator%20agents%20against%20carbapenem-resistant%20Enterobacterales.pdf?VersionId=A_Ld8bcFLUddgL9B6KE85WZfMo6vvuxJ 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1279_Five-year%20trend%20analysis%20of%20carbapenem-resistant%20Enterobacterales.pdf?VersionId=oD.Q.TxDcIlNrhHgVOiHC8z.KW8foCpo 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1286_In%20vitro%20Activity%20of%20Cefiderocol%20against%20Carbapenem-Nonsusceptible.pdf?VersionId=EuqFvSsRiYIW57mugycI5QnmWG4YNplX 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1287_In%20Vitro%20Activity%20of%20Cefiderocol%20against%20Resistant%20Subsets.pdf?VersionId=HrgZhAqebCEXqBxZZn2p46BXIWmbPT7A 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1310_Cefiderocol%20Remains%20Active%20Against%20US%20Clinical%20Isolates.pdf?VersionId=Kv_NYL1waXXKqKd2OXcnKtc.swV38aUt 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1352_Clinical%20Outcomes%20of%20Cefiderocol%20for%20Treatment.pdf?VersionId=eEzK3bSmHmWRAS9uwHzAyILOSKsFLw0x 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1353_Earlier%20Cefiderocol%20Use%20Was%20Associated%20with%20Better%20Outcomes.pdf?VersionId=fT_faEry54a1kde0Qvhd1pT7d7FlQROZ 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1354_Outcomes%20of%20Patients%20Treated%20With%20Cefiderocol.pdf?VersionId=lus_wVF1wmntd_uHjfu6akLS_P4f_Abu 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1606_Clearance%20of%20Infectious%20Virus%20in%20COVID-19%20Patients%20Treated%20With%20Ensitrelvir.pdf?VersionId=Zy4JATLoxVIwEB9U4GCptSSq80lUB.7f 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1666_Ensitrelvir%20(ESV)%20Population%20Pharmacokinetics%20(PK)%20in%20Nonhospitalized%20Adults%20with%20COVID-19.pdf?VersionId=aXP0BFYFeWDTVQp9rimsMms3neBsqQyV 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-11/APCCMI2025_Oral_Hibino_ANCHOR-02.pdf?VersionId=tsQwxJtIFmCDNx4ABdNIG31x2WcL6edY 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-11/GSA2025_Poster_Final_20251106.pdf?VersionId=gv1tsSMKyR.gVPTHtc49Bo7xqr6vfk1m 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2026-02/S-337395%20RSV_Final.pdf?VersionId=orAg5Io02O2OCoX61NSKFXcsIpq5TwUC 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2026-03/CROI2026_Poster0748.pdf?VersionId=R8Bd.53fTdPM3TZ0ZCUG_45vi6PAXkNX 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/infographic/node_539/Early%20Intervention%20in%20COVID-19%20May%20Reduce%20Clinical%20Complications%20and%20Further%20Community%20Transmission.pdf?VersionId=kp1WyBq1RRkpatoSRoGYQagtKDM3Sh0c 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/infographic/node_559/Early_Intervention_After_Exposure_to_SARS-CoV-2_Could_Reduce_the_Likelihood_of_Developing_COVID-19.pdf?VersionId=emenEKNhSWeTafsWFh1FOe6jGcSKz3Ni 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%20P0421%20Katsube%20T%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%20P0429%20Tashima%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%20P0543%20Miyazawa%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20IAS%202024/Added%20to%20asset%20delivery/Poster%20-%20Chew%20K%20et%20al.%202024%20International%20AIDS%20Conference.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20IDWeek%202024/Added%20to%20asset%20delivery/IDWeek2024_ETV%20Ph2b3%20long%20covid_final.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20IDWeek%202024/Added%20to%20asset%20delivery/IDWeek2024_ETV_Pre%20Exposure%20Prophylaxis.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20IDWeek%202024/Added%20to%20asset%20delivery/IDWeek2024_ETV_return%20to%20work_final.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Ensitrelvir%20IDWeek%202024/Added%20to%20asset%20delivery/IDWeek2024_ETV_RWE%20PMS%20Final.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/240418%20ECCMID_2024_PEDI-CEFI%20-%20V7-approved.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Longshaw_ECCMID%202024_Poster1374.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201360%20DeJonge%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201361%20DeJonge%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201367%20Nguyen%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201448%20Nguyen%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201578%20Ishibashi%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%201622%20Yamashiro%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%202523%20Ramirez%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%202524%20Perez-Pedrero%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%202525%20Saez%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%203185%20Dinh%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%203228%20Bleibtreu%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20ESCMID%202024/Added%20to%20asset%20delivery/Poster%20-%203734%20Sarda%20ESCMID%202024.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Activity%20of%20Cefiderocol%20and%20Comparator%20Agents%20Against%20Global%20Isolates%20of%20Stenotrophomonas.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Activity%20of%20CFDC%20CR%20nonsusceptible%20Enterobacterales.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Cefiderocol%20Remains%20Highly%20Active%20Against%20carbapenemase%20producing%20enterobacterales.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Cefiderocol%20Retains%20in%20vitro%20Activity%20Against%20Enterobacterales%20Non-Susceptible%20to%20βLactam%20β-Lactamase%20Inhibitor%20Combinations.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Correlation%20Analysis%20of%20Cefiderocol%20In%20vitro%20Activity%20and%20In%20vivo%20Efficacy%20against%20AB%20strains%20with%20DTR%20MIC%20endpoints.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/In%20vitro%20Activity%20of%20Cefiderocol%20and%20Comparator%20Agents%20Against%20Global%20Enterobacterales.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/In%20vitro%20Activity%20of%20Cefiderocol%20and%20Comparator%20Agents%20Against%20NonFermenter%20GramNegative.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/RWE%20PROVE.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20NACFC2024/Added%20to%20asset%20delivery/240916%20Cefiderocol%20poster_NACFC%202024_V8%20final%20to%20print.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/S-892216%20IDWeek%202024/Added%20to%20asset%20delivery/In%20vitro%20and%20in%20vivo%20antiviral%20activity.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/S-892216%20IDWeek%202024/Added%20to%20asset%20delivery/In%20Vitro%20Resistance%20Profiling.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/S-892216%20IDWeek%202024/Added%20to%20asset%20delivery/Therapeutic%20Effect%20of%20Delayed%20Treatment.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Xeruborbactam%20IDWeek%202024/Added%20to%20asset%20delivery/The%20Impact%20of%20Xeruborbactam%20on%20in%20vitro%20Activity%20of%20Cefiderocol.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Xeruborbactam%20IDWeek%202024/Added%20to%20asset%20delivery/Xeru%20Presentation.pdf 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-02/Fetroja%20–%20Availability%20of%20Antimicrobial%20Susceptibility%20Testing%20(AST)%20%20Resources.pdf?VersionId=MwxqaN10hifIvrr_7.1QR317YCpytN3M 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-03/Poster%20-%20Mendes%20RE%20et%20al.%20IDWeek%202024%20Sentry%20MBL%20PSA%20P1364_0.pdf?VersionId=rN9hCFkWddve4ox2oF8WH3FAux7xdp.1 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20carbapenem%20resistant%20Acinetobacter%20baumannii%20calcoaceticus%20complex%20including%20molecularly%20characterized%20clinical%20isolates%20causing%20infections%20in%20hospitals%20in%20European%20and%20adjacent%20reg.pdf?VersionId=rNRkViNEFPYkMVhIVe9xp4zNx2fOTwUd 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-04/Activity%20of%20cefiderocol%20against%20carbapenem-resistant%20Pseudomonas%20aeruginosa,%20including%20molecularly%20characterized%20clinical%20isolates,%20causing%20infections%20in%20hospitals%20in%20European%20and%20adjacent%20regions%202020%20to%202023.pdf?VersionId=e_Dssj_YSLOnxo3bbKHjSPxiTRAkkqSU 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_OP627_β-Lactam–β-Lactamase%20Inhibitor%20Combinations%20Show%20a%20High%20Degree%20of%20Cross-Resistance.pdf?VersionId=LqPX0Ckx1A1Jl0VgH4ezXL5RuzcQt8wy 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/IDWeek%202025_P1300_Activity%20of%20Cefiderocol%20and%20Comparator%20Agents%20Against%20Metallo-β-Lactamase.pdf?VersionId=h71xiKUWXiuunmuTpghBo9wZZ7o212wY 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/2025-10/NACFC%202025_P5_Cefiderocol%20Treatment%20for%20Gram-Negative%20Bacterial%20Infections_0.pdf?VersionId=Q.6UJlzG0UYkHLWvdreIz9cmbxoe4evZ 2026-10-14 https://www.shionogimedical.com/s3fs/s3fs-public/poster/Fetroja%20IDWeek2024/Added%20to%20asset%20delivery/Evaluation%20of%20Phenotypic%20Cross-Resistance%20Between%20Cefiderocol%20and%20βLactam%20βLactamase.pdf 2026-10-14